Abstract
Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined. Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis. Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis. Results: This statement identifies gaps in knowledge and develops potential research questions to further expand knowledge regarding risk, biologic mechanisms, clinical and radiologic presentation, and management of ICI-pneumonitis. Conclusions: Gaps in knowledge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the use of ICIs alone or combined with other therapies, highlight the importance in triaging research priorities for ICI-pneumonitis.
Original language | English (US) |
---|---|
Pages (from-to) | E31-E43 |
Journal | American journal of respiratory and critical care medicine |
Volume | 200 |
Issue number | 6 |
DOIs | |
State | Published - Sep 15 2019 |
Fingerprint
Keywords
- Immunotherapy
- Interstitial lung disease
- Lung cancer
- NSCLC
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
Cite this
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis An Official American Thoracic Society Research Statement. / Sears, Catherine; Rivera, M. Patricia; Camus, Philippe; Gaga, Mina; Garon, Edward B.; Gould, Michael K.; Limper, Andrew H.; Montgrain, Philippe R.; Naidoo, Jarushka; Nishino, Mizuki; Patel, Sandip P.; Peikert, Tobias; Possick, Jennifer D.; Travis, William D.
In: American journal of respiratory and critical care medicine, Vol. 200, No. 6, 15.09.2019, p. E31-E43.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis An Official American Thoracic Society Research Statement
AU - Sears, Catherine
AU - Rivera, M. Patricia
AU - Camus, Philippe
AU - Gaga, Mina
AU - Garon, Edward B.
AU - Gould, Michael K.
AU - Limper, Andrew H.
AU - Montgrain, Philippe R.
AU - Naidoo, Jarushka
AU - Nishino, Mizuki
AU - Patel, Sandip P.
AU - Peikert, Tobias
AU - Possick, Jennifer D.
AU - Travis, William D.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined. Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis. Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis. Results: This statement identifies gaps in knowledge and develops potential research questions to further expand knowledge regarding risk, biologic mechanisms, clinical and radiologic presentation, and management of ICI-pneumonitis. Conclusions: Gaps in knowledge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the use of ICIs alone or combined with other therapies, highlight the importance in triaging research priorities for ICI-pneumonitis.
AB - Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined. Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis. Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis. Results: This statement identifies gaps in knowledge and develops potential research questions to further expand knowledge regarding risk, biologic mechanisms, clinical and radiologic presentation, and management of ICI-pneumonitis. Conclusions: Gaps in knowledge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the use of ICIs alone or combined with other therapies, highlight the importance in triaging research priorities for ICI-pneumonitis.
KW - Immunotherapy
KW - Interstitial lung disease
KW - Lung cancer
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=85072155928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072155928&partnerID=8YFLogxK
U2 - 10.1164/rccm.201906-1202ST
DO - 10.1164/rccm.201906-1202ST
M3 - Article
C2 - 31518182
AN - SCOPUS:85072155928
VL - 200
SP - E31-E43
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 6
ER -